Pharmacists are likely to see people with COPD and asthma more regularly than a GP or nurse, so they play a pivotal role in educating patients on their medicines and inhaler technique.
Under the terms of the deal Bridge Biotherapeutics will receive upfront and near term payments of 45 million Euros and is eligible to receive up to more than 1.1 billion Euros in potential payments.